ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2454

Age-Adjusted Mortality Rate Trends in Systemic Sclerosis in the United States from 1999 to 2020
Abstract Number: 1636

Age-associated B Cells Contribute to Inflammation of Takayasu’s Arteritis in an Antibody-secreting Cell Differentiation Independent Manner
Abstract Number: 2239

Age, Seropositivity and Inflammation Determine Risk versus Benefit of Endogenous Estrogens on Coronary Atherosclerosis in Rheumatoid Arthritis
Abstract Number: 0203

Agreement of Administrative Pharmacy Dispensing with Patient-Reported Use of Oral Glucocorticoids in a Rheumatoid Arthritis Cohort
Abstract Number: 1063

AI –Driven Precision in Rheumatologic Emergencies: Unveiling the Capability of Top Healthcare Chatbots
Abstract Number: 0702

AISA 021, a Novel Calcium Channel Antagonist in Development for Raynaud’s & Systemic Sclerosis, Has Antagonistic Activity at Sodium Channel Targets for Pain Relief and Treats Scleroderma Pain Better Than Current Calcium Channel Blockers in a Phase 2A Study
Abstract Number: 1420

Alignment Between Rheumatology and Neurology of Nomenclature for Peripheral Nervous System Neuropathies
Abstract Number: 1214

All-Cause Mortality in Patients with Chronic Musculoskeletal Pain Using Pregabalin or Duloxetine: A Retrospective Cohort Study in US Veterans
Abstract Number: L17

Allogenic CD19 CAR NK Cells Therapy in Refractory Systemic Lupus Erythematosus: An Open-label, Single Arm, Prospective and Interventional Clinical Trial
Abstract Number: 0567

Alteration of JAK-STAT Signaling in an Axial Spondyloarthritispatient with TYK2 Variants
Abstract Number: 2604

Altered Expression of Ecto-5′-Nucleotidase (NT5E) in SLE Patients Based on Disease-associated Genotype
Abstract Number: 2293

Altered Expression of the MicroRNA Biogenesis Machinery Components Correlates with Inflammatory Parameters in Salivary Glands of Patient with Sjögren’s Disease
Abstract Number: 1834

Altered Mechanotransduction via Myosin II Contributes to Collagen and IL-6 Production in Systemic Sclerosis Skin
Abstract Number: 1269

Altered Tryptophan Metabolism in Juvenile Dermatomyositis Is Associated with Muscle Damage and Mental Health
Abstract Number: 0980

Ambient Air Pollution and Initiation of bDMARDs in Newly Diagnosed Rheumatoid Arthritis: A Nested Case-Control Study of NIH All of Us Cohort

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].